Erasca, Inc. (ERAS)

USD 1.58

(6.04%)

Market Cap (In USD)

447.56 Million

Revenue (In USD)

-

Net Income (In USD)

-125.04 Million

Avg. Volume

1.65 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.64-3.45
PE
-2.29
EPS
-0.69
Beta Value
1.161
ISIN
US29479A1088
CUSIP
29479A108
CIK
1761918
Shares
283266000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jonathan E. Lim M.D.
Employee Count
-
Website
https://www.erasca.com
Ipo Date
2021-07-16
Details
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.